C. Almansa, J. Alfon, A. F. De-arriba, F. L. Cavalcanti, I. Escamilla et al., Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors, p.5, 2003.

P. Angel and M. Karin, The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1072, issue.2-3, 1991.
DOI : 10.1016/0304-419X(91)90011-9

I. M. Avis, M. Jett, T. Boyle, M. D. Vos, T. Moody et al., Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling., Journal of Clinical Investigation, vol.97, issue.3, 1996.
DOI : 10.1172/JCI118480

E. Baciocchi, M. F. Gerini, and A. Lapi, Synthesis of sulfoxides by the hydrogen peroxide induced oxidation of sulfides catalysed by iron tetrakis(pentafluorophenyl)porphyrin: scope and chemoselectivity, 2004.

N. G. Bazan, V. Colangelo, and W. J. Lukiw, Prostaglandins and other lipid mediators in Alzheimer???s disease, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002.
DOI : 10.1016/S0090-6980(02)00031-X

. Methoxytetrahydropyrans, A new series of selective and orally potent 5-lipoxygenase inhibitors

L. M. Blomberg, M. R. Blomberg, P. E. Siegbahn, W. A. Van-der-donk, and A. Tsai, A quantum chemical study of the synthesis of prostaglandin G 2 by the cyclooxygenase active site, 2003.

P. R. Blower, The unique profile of nabumetone, 1992.

R. J. Boado, W. M. Pardridge, H. V. Vinters, and K. L. Black, Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family., Proceedings of the National Academy of Sciences, vol.89, issue.19, 1992.
DOI : 10.1073/pnas.89.19.9044

D. G. Bostwick, H. B. Burke, D. Djakiew, S. Euling, S. Ho et al., Human prostate cancer risk factors, Cancer, vol.17, issue.S10, pp.2371-2490, 2004.
DOI : 10.1002/cncr.20408

C. Brideau, S. Kargman, S. Liu, A. L. Dallob, E. W. Ehrich et al., A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors, Inflammation Research, vol.271, issue.2, pp.68-74, 1996.
DOI : 10.1007/BF02265118

C. D. Brooks and J. B. Summers, Modulators of Leukotriene Biosynthesis and Receptor Activation, Journal of Medicinal Chemistry, vol.39, issue.14, 1996.
DOI : 10.1021/jm960088k

E. M. Bruckheimer, S. Cho, S. Brisbay, D. J. Johnson, J. R. Gingrich et al., The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo, Oncogene, vol.19, issue.20, pp.2404-2412, 2000.
DOI : 10.1038/sj.onc.1203571

N. P. Buu-hoi, O. Roussel, and P. Jacquignon, Carcinogenic nitrogen compounds. Part XXXIX. A new synthesis of ?-carbolines and of 2, p.10, 1964.

C. Charlier and C. Michaux, Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs, European Journal of Medicinal Chemistry, vol.38, issue.7-8, 2003.
DOI : 10.1016/S0223-5234(03)00115-6

N. B. Chapman, K. Clarke, and H. Hugues, 250. Synthesis of some 5-substituted-2-methyltryptamines and their N-mono- and -di-alkyl derivatives, Journal of the Chemical Society (Resumed), 1965.
DOI : 10.1039/jr9650001424

E. J. Corey, P. T. Lansbury, . Jr, J. R. Cashman, and S. S. Kantner, Mechanism of the irreversible deactivation of arachidonate 5, p.6, 1984.

E. Costache, ? ? ? ?-carbolines et analogues, Nouvelles synthèses et étude des relations structure-activité cytotoxique et antitumorale, 1996.

. Methoxytetrahydropyrans, A new series of selective and orally potent 5-lipoxygenase inhibitor

G. Dannhardt and W. Kiefer, Cyclooxygenase inhibitors ??? current status and future prospects, European Journal of Medicinal Chemistry, vol.36, issue.2, 2001.
DOI : 10.1016/S0223-5234(01)01197-7

D. Leval, X. Julémont, F. Delarge, J. Pirotte, B. Dogné et al., New trends in dual 5-LOX, 2002.

R. Dietz, W. Nastainczyk, and H. H. Ruf, Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2, European Journal of Biochemistry, vol.242, issue.1-2, 1988.
DOI : 10.1016/S0010-8545(00)80316-1

J. M. Drazen, Asthma Therapy with Agents Preventing Leukotriene Synthesis or Action, Proceedings of the Association of American Physicians, vol.111, issue.6, 1999.
DOI : 10.1016/S0149-2918(97)80092-6

Y. Ducharme, C. Brideau, D. Dubé, C. Chan, J. Falgueyret et al., Naphtalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids, 1994.
DOI : 10.1021/jm00030a010

R. S. Eisenberg, Learning the Value of Drugs ??? Is Rofecoxib a Regulatory Success Story?, New England Journal of Medicine, vol.352, issue.13, pp.1285-1287, 2005.
DOI : 10.1056/NEJMp048358

J. Falgueyret, J. H. Hutchinson, and D. Riendeau, Criteria for the identification of non-redox inhibitors of, p.5, 1993.

R. A. Finnegan and H. W. Kutta, Organometallic chemistry. XII. The thermal decomposition of n-butyllithium, a kinetic study, 1965.

S. Fiorucci, R. Meli, M. Bucci, and G. Cirino, Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?11Abbreviations: NSAIDs, nonsteroidal anti-inflammatory drugs; COX, cyclooxygenase; LT, leukotriene; 5-LOX, 5-lipoxygenase; PG, prostaglandin; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsuphonyl)-phenyl-2(5H)-furanone; and DFP, diisopropyl fluorophosphate., Biochemical Pharmacology, vol.62, issue.11, pp.1433-1438, 2001.
DOI : 10.1016/S0006-2952(01)00747-X

G. A. Fitzgerald and C. Patrono, The coxibs, selective inhibitors of cyclooxygenase-2, 2001.

J. Franzone, T. Natale, and R. Cirillo, Effect of a new anti-inflammatory drug (oxamethacine) on the prostaglandin biosynthesis, Farmacol, vol.35, pp.498-503, 1980.

C. D. Funk, Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology, Science, vol.294, issue.5548, pp.1871-1875, 2001.
DOI : 10.1126/science.294.5548.1871

R. M. Garavito, M. G. Malkowski, and D. L. Dewitt, The structures of prostaglandin endoperoxide H synthases-1, p.2, 2002.

C. Guilloneau, A. Pierre, Y. Charton, N. Guilbaud, L. Kraus-berthier et al., ]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl)amide and Their 10- and 11-Methyl Analogues with Improved Antitumor Activity, Journal of Medicinal Chemistry, vol.42, issue.12, 1999.
DOI : 10.1021/jm981093m

J. Z. Haeggström, F. Kull, P. C. Rudberg, F. Tholander, and M. M. Thunnissen, Leukotriene A 4 hydrolase, Prostaglandins Other Lipid Mediat, pp.68-69, 2002.

. Cycloalkyl, -yl)benznesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2, p.522

C. J. Hawkey, COX-2 inhibitors, The Lancet, vol.353, issue.9149, pp.307-314, 1999.
DOI : 10.1016/S0140-6736(98)12154-2

S. H. Hong, I. Avis, M. D. Vos, A. Martinez, A. M. Treston et al., Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors, 1999.

M. M. Hoper, N. F. Voelkel, T. O. Bates, J. D. Allard, M. Horan et al., Prostaglandins Induce Vascular Endothelial Growth Factor in a Human Monocytic Cell Line and Rat Lungs via cAMP, American Journal of Respiratory Cell and Molecular Biology, vol.17, issue.6, 1997.
DOI : 10.1165/ajrcmb.17.6.2888

A. J. Hopfinger, Computer-assisted drug design, Journal of Medicinal Chemistry, vol.28, issue.9, 1985.
DOI : 10.1021/jm00147a001

N. M. Howarth, J. R. Malpass, and C. R. Smith, Manipulation of substituents at nitrogen in tropanes, homotropanes, and dehydro- derivatives, Tetrahedron, vol.54, issue.36, pp.10899-10914, 1998.
DOI : 10.1016/S0040-4020(98)00643-7

L. C. Hsi, L. C. Wilson, and T. E. Eling, Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma, 2002.

S. Huguenin, F. Vacherot, J. Fleury-feith, J. Riffaud, D. K. Chopin et al., Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal antiinflammatory drugs (NO-AINS) on human urological tumor cell lines, 2005.

M. Hughes-fulford, Y. Chen, and R. R. Tjandrawinata, Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells, Carcinogenesis, vol.22, issue.5, pp.701-707, 2001.
DOI : 10.1093/carcin/22.5.701

S. Ishikawa, S. Manabe, H. Yanagisawa, Y. Kitayawa, Y. Kani et al., Inhibitory effects of tryptophan pyrolysis products on human platelet aggregation through inhibition of prostaglandin endoperoxide synthetase, Food and Chemical Toxicology, vol.25, issue.11, 1987.
DOI : 10.1016/0278-6915(87)90261-4

K. Jennbacken, C. Vallbo, W. Wang, and J. E. Damber, Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis, The Prostate, vol.194, issue.2, 2005.
DOI : 10.1002/pros.20276

M. Jiang, S. B. Shappell, and S. W. Hayward, Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPAR?) signaling in prostate cancer, 2004.

Y. H. Jois and H. W. Gibson, Synthesis of 2-cyano-1,3-dibenzoyl-2,3-dihydrobenzimidazole: a novel Reissert compound from benzimidazole, The Journal of Organic Chemistry, vol.56, issue.2, pp.865-867, 1991.
DOI : 10.1021/jo00002a071

S. M. Jones, M. Luo, A. M. Healy, M. Peters-golden, and T. G. Brock, Structural and Functional Criteria Reveal a New Nuclear Import Sequence on the 5-Lipoxygenase Protein, Journal of Biological Chemistry, vol.277, issue.41, 2002.
DOI : 10.1074/jbc.M206070200

F. Julémont, J. M. Dogné, B. Pirotte, and X. De-leval, Recent Development in the Field of Dual COX / 5-LOX Inhibitors, Mini-Reviews in Medicinal Chemistry, vol.4, issue.6, 2004.
DOI : 10.2174/1389557043403747

A. S. Kalgutkar, A. B. Marnett, B. C. Crews, R. P. Remmel, and L. J. Marnett, Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors, Journal of Medicinal Chemistry, vol.43, issue.15, 2000.
DOI : 10.1021/jm000004e

S. Kambhampati, G. Ray, K. Sengupta, V. P. Reddy, S. K. Banerjee et al., Growth factors involved in prostate carcinogenesis, Frontiers in Bioscience, vol.10, issue.1-3, pp.1355-1367, 2005.
DOI : 10.2741/1625

S. Kargman, P. J. Vickers, and J. F. Evans, A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells, The Journal of Cell Biology, vol.119, issue.6, 1992.
DOI : 10.1083/jcb.119.6.1701

T. Kawamori, C. V. Rao, K. Seibert, and B. S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res, vol.58, pp.409-412, 1998.

U. Kelavkar, W. Glasgow, and T. E. Eling, The effect of 15-Lipoxygenase-1 expression on cancer cells, Current Urology Reports, vol.268, issue.3, 2002.
DOI : 10.1007/s11934-002-0066-8

G. J. Kelloff, R. Lieberman, V. E. Steele, C. W. Boone, R. A. Lubet et al., Chemoprevention of Prostate Cancer: Concepts and Strategies, European Urology, vol.35, issue.5-6, 1999.
DOI : 10.1159/000019906

F. A. Kerdesky, S. P. Schmidt, J. H. Holms, R. D. Dyer, G. W. Carter et al., Synthesis and 5-lipoxygenase inhibitory activity of 5-hydroperoxy-6, p.14, 1987.

N. Khorana, A. Purohit, K. Herrick-davis, M. Teitler, and R. A. Glennon, ??-Carbolines: binding at 5-HT5A serotonin receptors, Bioorganic & Medicinal Chemistry, vol.11, issue.5, 2003.
DOI : 10.1016/S0968-0896(02)00527-8

A. Kirschenbaum, X. Liu, S. Yao, and A. C. Levine, The role of cyclooxygenase-2 in prostate cancer, Urology, vol.58, issue.2, pp.127-131, 2001.
DOI : 10.1016/S0090-4295(01)01255-9

E. A. Klein, Chemoprevention of prostate cancer, 2005.

R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. Mcdonald, R. A. Stegeman et al., Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, vol.384, issue.6610, pp.644-648, 1996.
DOI : 10.1038/384644a0

M. Kuwahara, Y. Kawano, H. Shimazu, Y. Ashida, and A. Miyake, Synthetic studies on condensed-azole derivatives. IV. 1) Synthesis and anti-asthmatic activities of ?-sulfamoylalkyloxyimidazo, p.2, 1996.

M. Kuwahara, Y. Kawano, M. Kajino, Y. Ashida, and A. Miyake, Synthetic studies on condensed-azole derivatives. V. 1) Synthesis and anti-asthmatic activities of ?-sulfamoylalkyloxy, pp.4-5, 1997.

S. Lai and D. G. Lee, Lewis acid assisted permanganate oxidations, Tetrahedron, vol.58, issue.49, pp.9879-9887, 2002.
DOI : 10.1016/S0040-4020(02)01227-9

C. Leukotriene, A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes

C. Lee, T. Ohta, K. Shudo, and T. Okamoto, Some reactions of pyrido, p.3, 1981.

A. J. Lewis and D. E. Furst, Nonsteroidal anti-inflammatory drugs. Mechanisms ans clinical uses, 1994.

M. E. Lizarzaburu and S. J. Shuttleworth, -Tetrahydro-?-carbolinium salts: novel reactions with thiols, 2004.
DOI : 10.1016/j.tetlet.2004.04.078

P. Magnus, J. Rodriguez-lõpez, K. Mulholland, and I. Matthews, Biomimetic synthesis of the pentacyclic alkaloid (±)-Nirunine and possible biogenetic rearrangement of a precursor into, 1992.

T. Mano, R. W. Stevens, K. Ando, M. Kawai, K. Kawamura et al., Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate, 2005.

I. A. Mardini and G. A. Fitzgerald, Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs, 2001.

L. J. Marnett, Recent developments in cyclooxygenase inhibition, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002.
DOI : 10.1016/S0090-6980(02)00027-8

O. Melnyk, M. Zimmerman, K. J. Kim, and M. Shuman, NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL, The Journal of Urology, 1999.
DOI : 10.1097/00005392-199903000-00071

G. S. Merrick, W. M. Butler, K. E. Wallner, R. W. Galbreath, Z. Allen et al., Influence of body mass index on biochemical outcome after permanent prostate brachytherapy, Urology, vol.65, issue.1, pp.95-100, 2005.
DOI : 10.1016/j.urology.2004.08.044

C. Michaux, Elaboration d'un modèle de pharmacophore et d'interactions d'inhibiteurs sélectifs de la cyclooxygénase-2, 2004.

I. Morita, Distinct functions of COX-1 and COX-2, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, 2002.
DOI : 10.1016/S0090-6980(02)00029-1

D. Mukherjee, S. E. Nissen, and E. J. Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors, 2001.

C. Myers, A. Koki, R. Pamukcu, W. Wechter, and R. J. Padley, Proapoptotic anti-inflammatory drugs, Urology, vol.57, issue.4, pp.73-76, 2001.
DOI : 10.1016/S0090-4295(00)00945-6

K. Nithipatikom, N. D. Laabs, M. A. Isbell, and W. B. Campbell, Liquid chromatographic???mass spectrometric determination of cyclooxygenase metabolites of arachidonic acid in cultured cells, Journal of Chromatography B, vol.785, issue.1, 2003.
DOI : 10.1016/S1570-0232(02)00906-6

J. F. Ohd, C. K. Nielsen, J. Campbell, G. Landberg, H. Lofberg et al., Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas, Gastroenterology, vol.124, issue.1, pp.57-70, 2003.
DOI : 10.1053/gast.2003.50011

S. Okie, Raising the Safety Bar ??? The FDA's Coxib Meeting, New England Journal of Medicine, vol.352, issue.13, 2005.
DOI : 10.1056/NEJMp058055

M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk et al., Chemoprevention of intestinal polyposis in the Apc delta716 mouse by rofecoxib, 2001.

M. R. Panara, A. Greco, G. Santini, M. G. Sciulli, M. T. Rotondo et al., Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4- nitrophenyl]methanesulphonamide (NS-398) and 5-méthanesulphonamido-6, on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases, pp.4-5, 1995.

M. I. Patel, K. Subbaramaiah, B. Du, M. Chang, P. Yang et al., Celecoxib Inhibits Prostate Cancer Growth: Evidence of a Cyclooxygenase-2-Independent Mechanism, Clinical Cancer Research, vol.11, issue.5, 2005.
DOI : 10.1158/1078-0432.CCR-04-1877

H. Pham, T. Banerjee, and V. A. Ziboh, Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells, International Journal of Cancer, vol.292, issue.2, 2004.
DOI : 10.1002/ijc.20245

S. H. Pine and B. L. Sanchez, Formic acid-formaldehyde methylation of amines, The Journal of Organic Chemistry, vol.36, issue.6, 1971.
DOI : 10.1021/jo00805a022

N. Pommery and J. Hénichart, Involvement of PI3K/Akt pathway in prostate cancer, 2005.

M. Pouliot, P. P. Mcdonald, E. Krump, J. A. Mancini, S. R. Mccoll et al., Colocalization of Cytosolic Phospholipase A2, 5-Lipoxygenase, and 5-Lipoxygenase-Activating Protein at the Nuclear Membrane of A23187-Stimulated Human Neutrophils, European Journal of Biochemistry, vol.40, issue.1, 1996.
DOI : 10.1006/bbrc.1995.1388

W. S. Powell and J. Rokach, Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE, Progress in Lipid Research, vol.44, issue.2-3, 2005.
DOI : 10.1016/j.plipres.2005.04.002

P. Prasit, Z. Wang, C. Brideau, C. Chan, S. Charleson et al., The discovery of rofecoxib, MK 966, Vioxx ®5H)- furanone], an orally active cyclooxygenase-2 inhibitor, pp.4-4, 1999.

S. M. Prescott, Is cyclooxygenase-2 the alpha and the omega in cancer?, Journal of Clinical Investigation, vol.105, issue.11, pp.1511-1513, 2000.
DOI : 10.1172/JCI10241

P. Rocca, F. Marsais, A. Godard, and G. Queguiner, Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles., Tetrahedron, vol.49, issue.1, pp.49-64, 1993.
DOI : 10.1016/S0040-4020(01)80505-6

L. H. Rome and W. E. Lands, Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs., Proceedings of the National Academy of Sciences, vol.72, issue.12, 1975.
DOI : 10.1073/pnas.72.12.4863

R. H. Rynbrandt, E. E. Nishizawa, D. P. Balogoyen, A. R. Mendoza, and K. A. Annis, Synthesis and platelet aggregation inhibitory, p.5, 1981.

A. Santagati, A. Marrazzo, and G. Granata, Synthesis of potential selective COX-2 enzyme inhibitors derived from ethyl ester of 2-isothiocyanato-5-phenyl-3-thiophencarboxylic acid, 2003.

K. Sato, M. Hyodo, M. Aoki, X. Zheng, and R. Noyori, Oxidation of sulfides to sulfoxides and sulfones with 30% hydrogen peroxide under organic solvent- and halogen-free conditions, Tetrahedron, vol.57, issue.13, pp.2469-2476, 2001.
DOI : 10.1016/S0040-4020(01)00068-0

M. P. Seed, J. R. Brown, C. N. Freemantle, J. L. Papworth, P. R. Colville-nash et al., The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2, 1997.

D. R. Shaffer and H. I. Scher, Prostate cancer: a dynamic illness with shifting targets, The Lancet Oncology, vol.4, issue.7, pp.407-414, 2003.
DOI : 10.1016/S1470-2045(03)01138-0

W. L. Smith and I. Song, The enzymology of prostaglandin endoperoxide H synthases-1 and -2, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, p.2, 2002.
DOI : 10.1016/S0090-6980(02)00025-4

S. A. Snyder, D. A. Vosburg, M. G. Jarvis, and J. H. Markgraf, Intramolecular Hetero Diels???Alder Routes to ??-Carboline Alkaloids, Tetrahedron, vol.56, issue.30, pp.5329-5335, 2000.
DOI : 10.1016/S0040-4020(00)00468-3

L. A. Sorbera, P. A. Leeson, J. Castañer, and R. M. Castañer, Valdecoxib and Parecoxib Sodium, Drugs of the Future, vol.26, issue.2, pp.133-140, 2001.
DOI : 10.1358/dof.2001.026.02.610299

R. G. Spickett, Compounds affecting the central nervous system. II, pp.4-7, 1966.

G. Steinbach, P. M. Lynch, R. K. Phillips, M. H. Wallace, E. Hawk et al., The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis, New England Journal of Medicine, vol.342, issue.26, pp.1946-1952, 2000.
DOI : 10.1056/NEJM200006293422603

A. Tahri, K. J. Buysens, E. V. Van-der-eycken, D. M. Vandenberghe, and G. J. Hoornaert, Synthesis of ?-carbolines and ?-carbolines via intramolecular Diels-Alder reactions of, 1998.

D. G. Tang and A. T. Porter, Target to apoptosis: A hopeful weapon for prostate cancer, The Prostate, vol.224, issue.4, 1997.
DOI : 10.1002/(SICI)1097-0045(19970901)32:4<284::AID-PROS9>3.0.CO;2-J

S. Tries, W. Neupert, and S. Laufer, The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2, Inflammation Research, vol.51, issue.3, pp.135-143, 2002.
DOI : 10.1007/PL00000285

K. Tsuboi, Y. Sugimoto, and A. Ichikawa, Prostanoid receptor subtypes, Prostaglandins & Other Lipid Mediators, vol.68, issue.69, pp.68-69, 2002.
DOI : 10.1016/S0090-6980(02)00054-0

M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori et al., Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells, Cell, vol.93, issue.5, pp.705-716, 1998.
DOI : 10.1016/S0092-8674(00)81433-6

W. A. Van-der-donk, A. Tsai, and R. J. Kulmacz, The Cyclooxygenase Reaction Mechanism, Biochemistry, vol.41, issue.52, pp.15451-15458, 2002.
DOI : 10.1021/bi026938h

J. R. Vane, Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs, Nature New Biology, vol.231, issue.25, 1971.
DOI : 10.1038/newbio231232a0

M. Wagner, J. Loos, N. Weksler, M. Gantner, C. L. Corless et al., Resistance of prostate cancer cell lines to COX-2 inhibitor treatment, Biochemical and Biophysical Research Communications, vol.332, issue.3, 2005.
DOI : 10.1016/j.bbrc.2005.05.025

D. A. Walsh, S. K. Franzyshen, and J. M. Yanni, Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl)piperidines and structurally related compounds, Journal of Medicinal Chemistry, vol.32, issue.1, 1989.
DOI : 10.1021/jm00121a022

R. Wang, L. Lai, and S. Wang, Further development and validation of empirical scoring functions for structure-based binding affinity prediction, 2002.

A. Weber, A. Casini, A. Hrinr, D. Kuhn, C. T. Supuran et al., Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib:?? New Pharmacological Opportunities Due to Related Binding Site Recognition, Journal of Medicinal Chemistry, vol.47, issue.3, 2004.
DOI : 10.1021/jm030912m

C. S. Williams, A. J. Watson, H. Sheng, R. Helou, J. Shao et al., Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro models, 2000.

L. Xu, J. Cheng, and M. L. Trudell, Chromium (VI) oxide catalysed oxidation of sulfides to sulfones with periodic acid, 2003.

Y. Yang, A. R. Martin, D. L. Nelson, and J. Regan, Synthesis of some 5-substituted indoles, Heterocycles, vol.34, pp.1169-1175, 1992.

S. Zha, V. Yegnasubramanian, W. G. Nelson, W. B. Isaacs, D. Marzo et al., Cyclooxygenases in cancer: progress and perspective, Cancer Letters, vol.215, issue.1, pp.1-20, 2004.
DOI : 10.1016/j.canlet.2004.06.014

H. Zhang and R. C. Larock, Synthesis of beta-and gamma-carbolines by the palladium-catalyzed iminoannulation of internal alkynes, 2001.

L. Zhao and C. D. Funk, Lipoxygenase Pathways in Atherogenesis, Trends in Cardiovascular Medicine, vol.14, issue.5, pp.191-195, 2004.
DOI : 10.1016/j.tcm.2004.04.003

D. Zhao, F. Xu, . Chenc, R. D. Yillyer, E. J. Grabowski et al., Efficient syntheses of 2-(3???,5???-difluorophenyl)-3-(4???-methylsulfonylphenyl)cyclopent-2-enone, a potent COX-2 inhibitor, Tetrahedron, vol.55, issue.19, pp.6001-6018, 1999.
DOI : 10.1016/S0040-4020(99)00274-4

W. Zhu and D. Ma, Synthesis of Aryl Sulfones via L-Proline-Promoted CuI-Catalyzed Coupling Reaction of Aryl Halides with Sulfinic Acid Salts., ChemInform, vol.70, issue.34, 2005.
DOI : 10.1002/chin.200534112